GIS trade ideas
Gilead ST (Feb 4th 2021)Gilead (GILD) (February 4th 2021 through March 17th 2021)
Low: $63.74 - $64.15
High: $75 - $82 - $87
2020 Q4 reports are announced after market close today.
My expectations and speculations are as follows:
Year-ahead guidance to be positive.
EPS might not outperform the $2.04 analyst expectations.
I believe trading will still close positive tomorrow from the close of today. Trading today may close slightly negative.
I understand Gilead has some huge partnerships that will be working on a cure for HIV soon, or maybe has already started R&D in some aspects. I think even if the next immediate months are not bullish, I can definitely see a reason to be bullish in the long run.
Thanks for tuning in :) Disclaimer, anyone in the trade needs to do their own due diligence and decide what is right for YOU. My charts can be wrong at any time and it's very important that you have your own strategies and plans in place. I run this channel for my own educational purposes of learning to trade, and I will never be 100% right, so please do not let me confirm any bias for you! (Dangerous to do so, stay safe and remember the basics & rules of risk assessment.) Expect the unexpected and happy trading!
GILD is soooo frustrating ..... :(I don't know what's the deal with GILD and it's driving me crazy
- the price keeps teasing my breakeven :) -- only to bounce back down
- i was finally getting optimistic, thinking the curse have been lifted.. (see linked post) - not so sure now
- the sentiment went back into negative territory, so did the short term momentum (check the UTO indicator)
- Buy/Sell is in the "supply" zone (V.Viewer) -- or rather neutral with "no conviction"? -- we're in limbo mode with GILD for so long now.
i wanted to try and sell some Covered Call against my long position into the earnings, and leverage the (earning's) volatility to improve my BE - i can't even get a good price to sell at a strike equal to or slightly above my BE .... also volatility is so low for "earning times" - so no room to have a good play there.. Grrrrr!!!
should i give it more time or just give up on it ? and close it at a loss .. now i see couple of good recent moves in what seems to be attempts to finally bottom and break up - but it's just taking tooo long !
any thoughts from GILD experts?
breaking out of the red blanket in its daily chart.I'm trading it to my favorite moving average in its daily chart.
BUY GILDGood time to buy.
Currently starting a nice long Pos on GILD
Slow and steady on this beast as we could always dip more. buy the dips.
GL
GILD - The Sleeping Giant - Trend ReversalGILD - The Sleeping Giant - Trend Reversal
___________________
ENTRY = 56.56 Double Bottom - +64 confirmation
1st Target = .236fib@72.33
2nd Target = .382fib@82.08
3rd Target = .5fib@89.97
HOLD Target = .618@97.85+
JAN22 Call Leaps Still cheap
________________________________________________________________________________________________________________________
This content is for informational and educational purposes only. This is not in any way, shape or form financial or trading advice.
Good luck, happy trading and stay chill,
2degreez
$GILD ELLIOTWAVES$GILD is looking bullish going into 2021
We need a breakout of this downtrend channel for the impulsive waves to be valid, look for a break at the red trendline as well as a retest as support in wave 4
GILD double bottom on daily, Broke Down Trend, New HEPB Trials $Gild on 1/12 announced a partnership for a phase 2 trial on a new HEP B cure. It also got an upgrade on Jan 4th and it's covid treatment usage is going up due to rising covid numbers. Waiting for trigger of close above .618 fib for a weekly swing on this ticker. Overall Gild looks promising long term.
Gild LongYawn.. Up 8% on this.. Can't be arsed selling. But it's kinda dull, it aint heavy "metal" that's for sho.
$GILD Gilead Sciences Trendline Breakout.
Gilead has had a very poor 2020 and maybe 2021
brings fresh hope to the bulls.
Alert is set for a move above the 100ma @ $62.40.
Potential targets $63.76 $65.00 $65.57
RSI crossed above Mid Point
Volume impressive.
Gilead Sciences to $65-70I dislike Pharma as much as I dislike manipulation but GILD bounced off .618 fib and I like it. Seems like a $65-70 stock trading at a discount.
Solid 4.8% DIV yield in addition.
Dont forget these folks also have anti Rona stuff so it could all come together.
Long on GILD Gild after reaching 52 week low is also in oversold territory. After the acquisition news, still it has not moved up. Would be a good buy opportunity for long term. Short term targets are marked in the charts
GILEAD target price @104.6$ +84%Gilead activated a double bottom pattern with target at $104.6, +84% from current price. This structure would be inactivated below $55.80 so the stop loss would be around that zone. The risk/reward ratio is 45.
BUY $GILD - NR Picks Dec 06EN: Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California, that researches, develops and markets drugs in under-explored areas of medical need in the United States, Europe, and
internationally. Its products include treatments for human immunodeficiency virus (HIV) infection and liver disease.
It is currently at a key level of the last three months that could indicate a change in trend, being able to surpass its resistance of 61 - 62 and would reach the sell zone.
It should be mentioned that in recent years its dividend has increased from 2% in 2015 to 4% in 2020. December 14 is its cutoff date and it is scheduled to pay dividends on December 30.
In terms of its income structure, products related to HIV treatment represent 70% of its income, its main market being the United States.
ES: Gilead Sciences, Inc. es una compañía biofarmacéutica estadounidense con sede en Foster City, California, que investiga, desarrolla y comercializa medicamentos en áreas de necesidades médicas poco exploradas en los
Estados Unidos, Europa e internacionalmente. Sus productos incluyen tratamientos contra la infección por el virus de la inmunodeficiencia humana (VIH) y enfermedades hepáticas.
Actualmente se encuentra en un nivel clave de los últimos tres meses que podría indicar un cambio de tendencia, pudiendo sobrepasar su resistencia de los 61 – 62 y alcanzaría la zona de venta.
Cade mencionar que en los últimos años ha ido incrementado su dividendo pasando de 2% en el 2015 a un 4% en el 2020. El 14 de Diciembre es su fecha de corte y tiene programado pagar dividendos el 30 de Diciembre.
En cuanto a su estructura de ingresos los productos relacionados al tratamiento del VIH representan un 70% de sus ingresos siendo su mercado principal Estados Unidos.
